Slides
Page 1
Christoffer Rosenblad, CEO JPM January 14, 2026 Extending horizons in organ transplantation
Page 2
DOC ID: Disclaimer IMPORTANT: THE INFORMATION CONTAINED IN THIS PRESENTATION IS PRIVATE AND CONFIDENTIAL, HAS BEEN FURNISHED TO YOU SOLELY FOR YOUR INFORMATION AND MAY NOT BE REFERRED TO, QUOTED, REPRODUCED, REDISTRIBUTED OR DISCLOSED IN ANY WAY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON. BY REVIEWING THIS INFORMATION, YOU ARE ACKNOWLEDGING THE CONFIDENTIAL NATURE OF THIS INFORMATION AND ARE AGREEING TO ABIDE BY THE TERMS OF THIS DISCLAIMER. THIS CONFIDENTIAL INFORMATION IS BEING MADE AVAILABLE TO EACH RECIPIENT SOLELY FOR ITS INFORMATION AND IS SUBJECT TO AMENDMENT. You must read the following before continuing. The following applies to this document, any other material distributed, or sta tements made, in relation to the information in this document by XVIVO Perfusion AB (publ) (the “Company ”) or any person on behalf of the Company, and any question-and-answer session that follows any presentation (collectively, the “Information ”). By attending the meeting where the Information is presented, or by reading the Information, you agree to be bound by the fol lowing terms and conditions. The Information does not constitute or form part of, and should not be construed as, an offer or the solicitation of an offer to subscribe for or purchase securities of the Company, and nothing contained herein shall form the basis of or be relied on in connection with any contract or commitment whatsoever. The Information may not be viewed by any persons located within the United States other than “qualified institutional buyers” as defined in Rule 144A under the U.S. Securities Act of 1933, as amended (the “Securities Act ”). In addition, this document does not constitute a “prospectus” within the meaning of the EU Prospectus Regulation (2017/1129). The Information may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in who le or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or ent ity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would requir e any registration or licensing within such jurisdiction. The Information is not for publication, release or distribution in the United States, the United Kingdom, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful. If this document has been received in error , it must be immediately returned to the Company. The Information has not been independently verified. No representation or warranty, express or implied, is made as to, and no reliance should be placed upon, the fairness, accuracy, completeness or correctness of the Information. The Company accepts no responsibility in this respect. The merit and suitability of any investment in the Company should be independently evaluated and any such investment should be s ubject to independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an inv estment. The recipient acknowledges that it makes any investment decisions in reliance on its own judgment and not in reliance of the Company. The Company shall have no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from the Information, nor shall the Company accept any responsibility whatsoever for, or make any representation or warranty, express or implied, a s to, the truth, fullness, accuracy or completeness of the Information (or whether any information has been omitted therefrom) or any other information relating to the Company, its sub sidiaries or associated companies, in any form whatsoever, howsoever transmitted or made available, or for any loss howsoever ar ising from any use of the Information or otherwise arising in connection therewith. In addition, no duty of care or otherwise is owed or will be deemed to be owed by any such pers on to recipients of the Information or any other person in relation to the Information. The Information includes statistics, data and other information relating to addressable markets, market shares, market positions and other industry data pertaining to the Company’s business and markets. Such information is based on the Company’s analysis of multiple sources and, in some instances, assumptions from the Company. As far as the Company is aware from such information, no facts have been omitted which would re nder the information provided inaccurate or misleading. The Information contains forward-looking statements. All statements other than statements of historical fact included in the Inf ormation are forward-looking statements. Forward-looking statements give the Company’s current expectations and projections rela ting to its financial condition, result of operations, plans, objectives, future performance and business. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target”, “believe”, “expect”, “aim”, “intend”, “may”, “anticipate”, “estimate”, “plan” , “project”, “will”, “can have”, “likely”, “should”, “would”, “could” and other words and terms of similar meaning or the negative thereof. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company’s control that could cause the Company’s actual r esults, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward -looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strat egies and the environment in which it will operate in the future. The Information, including but not limited to forward-looking statements, applies only as of the date hereof and is not intended to give any assurance as to future results. The Company disclaims any obligations or undertakings to disseminate any updates or revisions to the Information, including any financial data or forward-looking statements, and will not publicly release any revisions it may make to the Information that may result f rom any change in the Company’s expectations, any change in events, conditions or circumstances on which these forward -looking statements are based, or other events or circumstances arising after the date hereof. Market data used in the Information not attributed to a specific source are estimat es of the Company and have not been independently verified. The Information is subject to Swedish law and any dispute arising in respect hereof is subject to the exclusive jurisdiction of the Swedish courts with Stockholm district court as the first instance. XVIVO_JPM_2026
Page 3
DOC ID: Today’s presenter Christoffer Rosenblad CEO XVIVO_JPM_2026
Page 4
Nobody should die waiting for a new organ. Alex Moroianu Heart recipient Australia Far too many patients do not receive the help they need in time due to the acute shortage of transplantable organs. At XVIVO, we’re determined to change this.
Page 5
DOC ID: We believe in an extended life of organs Nobody should die waiting for a new organ Diagnostics Organ matching Donor Care Organ recovery Organ preservation Organ assessment Transplant Immuno- suppresants Post- surgical care We offer technologies and services for organ recovery, preservation and machine perfusion for all major organs Pre-Transplant (In vivo) During-Transplant (Ex vivo) Post-Transplant XVIVO_JPM_2026
Page 6
DOC ID: Strong presence in leading transplant markets Main markets Founded 1998 Employees ~200 The share is listed on Nasdaq Stockholm mid-cap Business areas Global leading all organ company in a rapidly growing transplant market Thoracic Abdominal Services XVIVO_JPM_2026 Americas 60% EMEA 35% APAC 5% Key Financials Net Sales R12 85M USD EBITDA R12 19% CAGR 2020-2024 35% R12 Q4 2024 – Q3 2025
Page 7
DOC ID: The transplant market DOC ID: XVIVO_JPM_2026
Page 8
DOC ID: The global need All organs Approximately, 1.7 million organ transplants are required every year. With only 170,000 organ transplants performed globally each year, this only covers of the total need 1 ~10% 1. Those [2021] data are based on the Global Observatory on Donation and Transplantation (GODT) data, produced by the WHO -ONT collaboration. Available from: https://www.transplant-observatory.org/who-ont/ Statistics for 2022 are not yet available at global level. XVIVO_JPM_2026
Page 9
DOC ID: Organ utilization opportunity Utilization rates - US averages (2024) 20% 27% 64% 64% Lung Heart Liver Kidney XVIVO_JPM_2026
Page 10
DOC ID: 0 2 4 6 8 10 12 14 16 18 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Thousands DBD DCD Changing dynamics driving rapid market growth DBD Donor Pool: 50% DBD Transplants: 70% DCD Donor pool: 50% DCD Transplants: 30% DBD – Donation after brain death DCD DCD - Donation after circulatory death Increasing the donor pool through new donor groups (e.g. extended criteria) Significant potential in increasing DCD transplant rates Transplant volumes expected to grow exponentially due to dual growth effect: • Donor pool expansion • Improved organ utilisation New technologies facilitating the expansion of the donor pool and increasing organ utilization. Donors recovered in the USA XVIVO_JPM_2026 DBD DCD Transplants CAGR 2023-2025: +9% +11% All organs Lung tx
Page 11
DOC ID: Solving the problem DOC ID: XVIVO_JPM_2026
Page 12
DOC ID: From market leaders in lung preservation to a beyond product portfolio Lung Heart Kidney & Liver Service Born from lung transplantation – now with more than 25 years of market leadership Expanded to a full thoracic portfolio with paradigm changing heart technology World’s first all organ company with the acquisition of market leading technologies within kidney and liver Expansion beyond product to address limitations in the transplant system Becoming the preferred partner in the transplant process XVIVO_JPM_2026
Page 13
XVIVO’s offering – Best in class Products XPS | STEEN Solution | PERFADEX® Plus Services XVIVO Organ Recovery Service XVIVO Organ Perfusion Service XVIVO Insights XVIVO FlowHawk LUNG HEART KIDNEY LIVER Kidney Assist Transport | Kidney Assist XVIVO Heart Assist Transport * | XVIVO Heart Solution | XVIVO Heart Solution Supplement * XVIVO Heart Assist Transport is for clinical investigation only, it is not commercially available. NOTE: All products are not available in all markets. XVIVO Group has two legal manufacturers represented. Liver Assist
Page 14
DOC ID: Regulatory approval status in core markets PMA approval for STEEN Solution & XPS / PERFADEX 510(k) cleared Kidney Assist Transport 510(k) cleared IDE application approved Regulatory strategy under re-evaluation STEEN Solution, XPS & PERFADEX CE marked Kidney Assist Transport CE marked Liver Assist CE marked STEEN Solution, XPS & PERFADEX approved by the TGA Kidney Assist Transport approved by the TGA Liver Assist approved by the TGA * Products not approved for commercial sales Patient inclusion in US trial completed Study results expected to be announced in Q2, 2026 Patient inclusion in European trial completed Regulatory process on-going Patient inclusion in ANZ trial completed Regulatory process on-going * * * * XVIVO_JPM_2026
Page 15
DOC ID: XVIVO is reshaping the industry XVIVO_JPM_2026 Making more organs available for transplant Improving the lives for patients through better outcomes Reducing costs in the transplant system by improving efficiency Reshaping how transplants are performed – making procedures plannable
Page 16
DOC ID: XVIVO is unique in the market Our competitive advantage Optimising preservation through HOPE Hypothermic oxygenated perfusion Bringing true innovation to market Perfusate Only company to have brought new and optimised perfusion solutions to the market Driving the market forward Research Extensive body of clinical evidence across all major organs in leading publications XVIVO_JPM_2026
Page 17
DOC ID: Outlook DOC ID: XVIVO_JPM_2026
Page 18
DOC ID: XVIVO_JPM_2026 XVIVO is changing the world Short-term focus USA: • Drive EVLP adoption in the US by leveraging perfusion service models • Establish standardized NRP procurement as a core XVIVO service offering in the US • Submission of the regulatory file to the FDA for XVIVO Heart Assist Transport including presentation of 12- month data • Continued investment in US commercial organization to support EVLP expansion and heart commercialization Europe: • Obtaining CE -mark and start commercialization of XVIVO Heart Assist Transport-technology in Europe
Page 19
DOC ID: Changing the paradigm of heart preservation Unprecedented distance covered: 6750km or 3659nm Extended preservation time: 12h06m out-of-body Commercial air transport Economy seat XVIVO heart technology makes first cross Atlantic heart transplant possible: XVIVO_JPM_2026
Page 20
DOC ID: XVIVO as an investment High growth potential, contributing to saving more lives in a rapidly changing market Market potential for machine perfusion is 10x larger than current standard of care History of continuous profitable growth and high margins Future secured product portfolio and track-record of successfully bringing innovation to market XVIVO’s offer increases the availability of transplantable organs 1 2 3 4 XVIVO_JPM_2026
Page 21
Nobody should die waiting for a new organ.
Page 22
XVIVO Perfusion AB | Entreprenörsstråket 10 | SE-431 53 Mölndal | Sweden Tel +46 31 788 21 50 | xvivogroup.com XVIVO trademarks, names and logos are registered trademarks of XVIVO Perfusion AB. © 2023 XVIVO Perfusion AB. All rights reserved.2026